Amgen to Use Illumina Genotyping Technology in Large Women's Health Study | GenomeWeb
NEW YORK (GenomeWeb News) — Illumina today said that Amgen will use its genotyping technology as part of a large women's health study. 
Under the agreement, Illumina will provide its HumanHap300-Duo BeadChip to Amgen, which will work with researchers at the Brigham and Women’s Hospital to genotype women who have been clinically tracked for a decade.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.